Citius Pharmaceuticals Reports 2025 Year-End Results
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a biopharmaceutical company dedicated to developing innovative critical care products, has revealed significant updates on its business and financial performance for the fiscal year ending September 30, 2025. The highlight was the successful launch of LYMPHIR™, a groundbreaking cancer immunotherapy, which aims to provide relief for patients suffering from cutaneous T-cell lymphoma (CTCL).
Key Developments in 2025
During 2025, Citius Pharma achieved notable milestones, including the rollout of LYMPHIR™, following its FDA approval. Leonard Mazur, Chairman and CEO, expressed that this launch not only marks a pivotal turning point for the company but is also the first systemic therapy for CTCL patients since 2018. He emphasized the company’s ongoing commitment to meeting the needs of patients with limited treatment options.
Broader Market Engagement
The company made significant strides to ensure the effective launch of LYMPHIR™, including forming strategic partnerships and agreements with major U.S. pharmaceutical wholesalers for distribution. This effort guarantees nationwide availability for patients needing this essential therapy. Furthermore, Citius Pharma secured access to LYMPHIR in 19 international markets, enabling entry through named patient programs (NPPs), thus broadening their reach globally.
Financial Highlights
For the fiscal year, Citius Pharmaceuticals reported cash and cash equivalents totaling $4.3 million as of September 30, 2025. Notably, the company did not generate revenue during this period, owing to its focus on the development and launch of LYMPHIR™. Total research and development expenses were recorded at $9.2 million, a decline from $11.9 million the previous year, while general and administrative expenses increased slightly to $18.5 million from $18.2 million, reflecting the ongoing operational needs associated with launching a new product.
Looking Ahead to 2026
With LYMPHIR™ now commercially available, Citius Pharmaceuticals is concentrated on driving its adoption throughout 2026. The anticipated expansion will not only fortify the company's market position but also enhance the potential for patient treatment options. The strategic vision includes actively engaging with the FDA on advancing additional drug candidates, such as Mino-Lok, to explore even more opportunities for patient care.
Investor and Market Strategy
As Citius Pharma looks forward to capitalizing on its developments, it has successfully raised approximately $61 million through various capital financing initiatives. This financial backing enables the company to strengthen its infrastructure and product pipeline further. The initial projected market for LYMPHIR is estimated to exceed $400 million, indicating a significant opportunity that the company seeks to harness effectively.
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), is devoted to the development and commercialization of first-in-class critical care products aimed at patients with serious medical conditions. The company focuses on delivering innovative solutions, including LYMPHIR™ and other products in its late-stage pipeline, such as Mino-Lok, a catheter lock solution, and CITI-002 (Halo-Lido), a topical treatment for hemorrhoids.
Frequently Asked Questions
1. What was the main achievement for Citius Pharmaceuticals in 2025?
The main achievement was the launch of LYMPHIR™, an FDA-approved immunotherapy for CTCL patients.
2. How did Citius Pharmaceuticals perform financially in 2025?
The company reported no revenues, with cash equivalents at $4.3 million, and raised approximately $61 million through capital financing.
3. What are the future plans for LYMPHIR™?
Citius Pharma plans to focus on promoting the adoption of LYMPHIR™ in the market and looks to engage the FDA for future developments.
4. What other products are in Citius Pharma's pipeline?
In addition to LYMPHIR™, the pipeline includes Mino-Lok and CITI-002 (Halo-Lido), addressing severe medical needs.
5. How does Citius Pharma plan to sustain its growth?
The company aims to strengthen its operational foundation through strategic partnerships, ongoing FDA engagements, and proactive market strategies.
